Understanding -Host Interactions: The Ongoing Quest for an Efficacious Vaccine

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2020 Dec 9

PMID 33291484

Citations 33

Authors

Maite Sainz-Mejias

Irene Jurado-Martin

Siobhan McClean

Affiliations

Soon will be listed here.

Abstract

is a leading cause of chronic respiratory infections in people with cystic fibrosis (CF), bronchiectasis or chronic obstructive pulmonary disease (COPD), and acute infections in immunocompromised individuals. The adaptability of this opportunistic pathogen has hampered the development of antimicrobial therapies, and consequently, it remains a major threat to public health. Due to its antimicrobial resistance, vaccines represent an alternative strategy to tackle the pathogen, yet despite over 50 years of research on anti- vaccines, no vaccine has been licensed. Nevertheless, there have been many advances in this field, including a better understanding of the host immune response and the biology of . Multiple antigens and adjuvants have been investigated with varying results. Although the most effective protective response remains to be established, it is clear that a polarised Th2 response is sub-optimal, and a mixed Th1/Th2 or Th1/Th17 response appears beneficial. This comprehensive review collates the current understanding of the complexities of -host interactions and its implication in vaccine design, with a view to understanding the current state of vaccine development and the direction of future efforts. It highlights the importance of the incorporation of appropriate adjuvants to the protective antigen to yield optimal protection.

Citing Articles

Vaccine Development: Lessons, Challenges, and Future Innovations.

Santamarina-Fernandez R, Fuentes-Valverde V, Silva-Rodriguez A, Garcia P, Moscoso M, Bou G Int J Mol Sci. 2025; 26(5).

PMID: 40076637 PMC: 11900337. DOI: 10.3390/ijms26052012.

Understanding the pathophysiology of colonization as a guide for future treatment for chronic leg ulcers.

Matheus G, Chamoun M, Khosrotehrani K, Sivakumaran Y, Wells T Burns Trauma. 2025; 13():tkae083.

PMID: 39830194 PMC: 11741523. DOI: 10.1093/burnst/tkae083.

Effects of Yersinia pseudotuberculosis outer membrane vesicles on Pseudomonas aeruginosa antigens immune response.

Duan Z, Song J, Zhang M, Zhang Z, Li N, Fu Y PLoS One. 2024; 19(12):e0310652.

PMID: 39705292 PMC: 11661608. DOI: 10.1371/journal.pone.0310652.

Molecular characteristics and antibiotic resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa in Nanning, China.

Wei X, Liu M, Mo C, Tan R, Li S, Liang H BMC Microbiol. 2024; 24(1):478.

PMID: 39548364 PMC: 11566251. DOI: 10.1186/s12866-024-03640-7.

Pseudomonas aeruginosa elongation factor-Tu (EF-Tu) is an immunogenic protective protein antigen.

Moustafa D, Lou E, Schafer-Kestenman M, Mateu-Borras M, Domenech-Sanchez A, Alberti S Vaccine. 2024; 42(26):126476.

PMID: 39476472 PMC: 11645190. DOI: 10.1016/j.vaccine.2024.126476.

References

Neill D, Saint G, Bricio-Moreno L, Fothergill J, Southern K, Winstanley C . The B lymphocyte differentiation factor (BAFF) is expressed in the airways of children with CF and in lungs of mice infected with Pseudomonas aeruginosa. PLoS One. 2014; 9(5):e95892. PMC: 4029587. DOI: 10.1371/journal.pone.0095892. View

Gellatly S, Hancock R . Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis. 2013; 67(3):159-73. DOI: 10.1111/2049-632X.12033. View

Pennington J . Preliminary investigations of Pseudomonas aeruginosa vaccine in patients with leukemia and cystic fibrosis. J Infect Dis. 1974; 130 Suppl(0):S159-62. DOI: 10.1093/infdis/130.supplement.s159. View

Staczek J, Bendahmane M, Gilleland L, Beachy R, Gilleland Jr H . Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein F of Pseudomonas aeruginosa provides protection against challenge with P. aeruginosa. Vaccine. 2000; 18(21):2266-74. DOI: 10.1016/s0264-410x(99)00571-x. View

Faezi S, Bahrmand A, Siadat S, Nikokar I, Sardari S, Mahdavi M . Construction, expression, purification and characterization of secretin domain of PilQ and triple PilA-related disulfide loop peptides fusion protein from . Iran J Basic Med Sci. 2017; 20(5):458-466. PMC: 5478772. DOI: 10.22038/IJBMS.2017.8667. View

Lee K, Sheth H, Wong W, Sherburne R, Paranchych W, Hodges R . The binding of Pseudomonas aeruginosa pili to glycosphingolipids is a tip-associated event involving the C-terminal region of the structural pilin subunit. Mol Microbiol. 1994; 11(4):705-13. DOI: 10.1111/j.1365-2958.1994.tb00348.x. View

Mann E, Wozniak D . Pseudomonas biofilm matrix composition and niche biology. FEMS Microbiol Rev. 2012; 36(4):893-916. PMC: 4409827. DOI: 10.1111/j.1574-6976.2011.00322.x. View

Jiang M, Yao J, Feng G . Protective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa Infection. PLoS One. 2014; 9(5):e96609. PMC: 4006881. DOI: 10.1371/journal.pone.0096609. View

Burrows L . Pseudomonas aeruginosa twitching motility: type IV pili in action. Annu Rev Microbiol. 2012; 66:493-520. DOI: 10.1146/annurev-micro-092611-150055. View

10.

Cendra M, Christodoulides M, Hossain P . Signaling Mediated by Toll- Receptor 5 Sensing of Flagellin Influences IL-1β and IL-18 Production by Primary Fibroblasts Derived from the Human Cornea. Front Cell Infect Microbiol. 2017; 7:130. PMC: 5395653. DOI: 10.3389/fcimb.2017.00130. View

11.

Zuercher A, Imboden M, Jampen S, Bosse D, Ulrich M, Chtioui H . Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clin Exp Immunol. 2005; 143(1):132-8. PMC: 1809560. DOI: 10.1111/j.1365-2249.2005.02964.x. View

12.

Young L, Meyer R, Armstrong D . Pseudomonas aeruginosa vaccine in cancer patients. Ann Intern Med. 1973; 79(4):518-27. DOI: 10.7326/0003-4819-79-4-518. View

13.

Saha S, Takeshita F, Sasaki S, Matsuda T, Tanaka T, Tozuka M . Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. Vaccine. 2006; 24(37-39):6240-9. DOI: 10.1016/j.vaccine.2006.05.077. View

14.

Yang F, Gu J, Yang L, Gao C, Jing H, Wang Y . Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models. Sci Rep. 2017; 7(1):3957. PMC: 5479855. DOI: 10.1038/s41598-017-04029-5. View

15.

Castric P, Deal C . Differentiation of Pseudomonas aeruginosa pili based on sequence and B-cell epitope analyses. Infect Immun. 1994; 62(2):371-6. PMC: 186117. DOI: 10.1128/iai.62.2.371-376.1994. View

16.

Tolle L, Yu F, Kovach M, Ballinger M, Newstead M, Zeng X . Redundant and cooperative interactions between TLR5 and NLRC4 in protective lung mucosal immunity against Pseudomonas aeruginosa. J Innate Immun. 2014; 7(2):177-86. PMC: 4348217. DOI: 10.1159/000367790. View

17.

Chen K, McAleer J, Lin Y, Paterson D, Zheng M, Alcorn J . Th17 cells mediate clade-specific, serotype-independent mucosal immunity. Immunity. 2011; 35(6):997-1009. PMC: 3406408. DOI: 10.1016/j.immuni.2011.10.018. View

18.

Cross A, Sadoff J, Iglewski B, Sokol P . Evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in humans. J Infect Dis. 1980; 142(4):538-46. DOI: 10.1093/infdis/142.4.538. View

19.

Del Giudice G, Rappuoli R, Didierlaurent A . Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018; 39:14-21. DOI: 10.1016/j.smim.2018.05.001. View

20.

Farajnia S, Najar Peerayeh S, Tanomand A, Majidi J, Goudarzi G, Naghili B . Protective efficacy of recombinant exotoxin A--flagellin fusion protein against Pseudomonas aeruginosa infection. Can J Microbiol. 2014; 61(1):60-4. DOI: 10.1139/cjm-2014-0501. View